Richard Bernstein Advisors LLC Sells 18,526 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Richard Bernstein Advisors LLC trimmed its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 55.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,184 shares of the medical equipment provider’s stock after selling 18,526 shares during the period. Richard Bernstein Advisors LLC’s holdings in Zimmer Biomet were worth $1,496,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Key Financial Inc boosted its holdings in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. increased its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 149 shares in the last quarter. Finally, Mather Group LLC. acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $36,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $91.78 on Wednesday. The company has a fifty day moving average price of $92.21 and a 200-day moving average price of $95.41. The firm has a market cap of $17.96 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 1.91 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ZBH. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective for the company. in a report on Friday, January 9th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. UBS Group restated a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, BTIG Research reiterated a “buy” rating and set a $112.00 price target on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.